Overview

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

Status:
Active, not recruiting
Trial end date:
2026-10-10
Target enrollment:
Participant gender:
Summary
This is a phaseⅠb/Ⅱ, open-label, two-arm parallel study evaluating the efficacy and safety of different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fudan University